Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 203.18

-1.4%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve who wrote (29585)	12/13/1999 2:18:00 PM
From: Cheryl Galt	Read Replies (1) of 32384

biz.yahoo.com December 13, 1:56 pm Eastern Time Ligand cancer drug Targretin wins US panel support BETHESDA, Md., Dec 13 (Reuters) - A U.S. federal advisory panel on Monday backed Ligand Pharmaceuticals' experimental drug Targretin as a treatment for advanced stages of a rare type of lymphoma. Ligand is seeking the Food and Drug Administration's approval to market Targretin for alleviating symptoms of cutaneous T-cell lymphoma, a cancer that afflicts about 16,000 people in the United States. The FDA advisory panel voted 13-2 with one abstention that Targretin was safe and effective for treating advanced stages of the disease, which cannot be cured and now has limited treatments. The committee, however, voted 7-5 with four abstentions against recommending approval for giving the drug to patients in early stages of the disease. The panel's opinion is important because the FDA usually follows its panels' advice. San Diego-based Ligand, a biotechnology firm that hopes to turn a profit next year, has said Targretin is central to its future growth. Ligand sells two other drugs and is studying Targretin as a possible treatment for breast cancer and psoriais.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next